Crossmark

Filovirus vaccines as a response paradigm for emerging infectious diseases

Published Online: 2024-10-11

Authors

Marzi, Andrea https://orcid.org/0000-0003-0186-9587
Feldmann, Heinz https://orcid.org/0000-0001-9448-8227
Funding

Funding for this research was provided by:

Intramural Research Program, NIAID, NIH
License Information

Text and Data Mining valid from 2024-10-11

Version of Record valid from 2024-10-11
More Information

Article History

Received: 16 June 2024

Accepted: 25 September 2024

First Online: 11 October 2024

Competing interests

: A.M. declares no competing interests. H.F. claims intellectual property for VSV-based filovirus vaccines.

Document is current